Abstract:Non-alcoholic fatty liver disease (NAFLD) encompasses the simple steatosis to more progressive steatosis with associated hepatitis, fibrosis, cirrhosis, and in some cases hepatocellular carcinoma. NAFLD is a growing epidemic, not only in the United States, but worldwide in part due to obesity and insulin resistance leading to liver accumulation of triglycerides and free fatty acids. Numerous risk factors for the development of NAFLD have been espoused with most having some form of metabolic derangement or insulin resistance at the core of its pathophysiology. NAFLD patients are at increased risk of liver-related as well as cardiovascular mortality, and NAFLD is rapidly becoming the leading indication for liver transplantation. Liver biopsy remains the gold standard for definitive diagnosis, but the development of noninvasive advanced imaging, biochemical and genetic tests will no doubt provide future clinicians with a great deal of information and opportunity for enhanced understanding of the pathogenesis and targeted treatment. As it currently stands several medications/supplements are being used in the treatment of NAFLD; however, none seem to be the "magic bullet" in curtailing this growing problem yet. In this review we summarized the current knowledge of NAFLD epidemiology, risk factors, diagnosis, pathogenesis, pathologic changes, natural history, and treatment in order to aid in further understanding this disease and better managing NAFLD patients.

Nonalcoholic Fatty Liver Disease: Molecular Pathways and Therapeutic Strategies

Nonalcoholic fatty liver disease: molecular pathways and therapeutic strategies

Shedding light on non-alcoholic fatty liver disease: Pathogenesis, molecular mechanisms, models, and emerging therapeutics

Emerging Molecular Targets for Treatment of Nonalcoholic Fatty Liver Disease

Emerging targets and potential therapeutic agents in non-alcoholic fatty liver disease treatment

Molecular Mechanism Pathways of Natural Compounds for the Treatment of Non-Alcoholic Fatty Liver Disease

Diagnostic and therapeutic strategies for non-alcoholic fatty liver disease

Current insights in molecular characterization of non-alcoholic fatty liver disease and treatment

Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)

Pharmacotherapy for Non-Alcoholic Fatty Liver Disease: Emerging Targets and Drug Candidates

Insights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases

Emerging novel targets for nonalcoholic fatty liver disease treatment: Evidence from recent basic studies

Current, emerging, and potential therapies for non-alcoholic steatohepatitis

Emerging mechanisms of non-alcoholic steatohepatitis and novel drug therapies

Non-alcoholic fatty liver disease: An expanded review

Advances in the Diagnosis and Treatment of Non-Alcoholic Fatty Liver Disease

Pathogenetic Pathways in Nonalcoholic Fatty Liver Disease

The New Therapeutic Approaches in the Treatment of Non-Alcoholic Fatty Liver Disease

Progress and challenges in the prevention and control of nonalcoholic fatty liver disease

Progress of potential drugs in non-alcohol fatty liver disease

Nonalcoholic Fatty Liver Disease: Pathogenesis and Therapeutics from a Mitochondria-Centric Perspective.